Taysha Gene Therapies (TSHA) Cash from Operations (2020 - 2026)

Taysha Gene Therapies has disclosed Cash from Operations across 7 years of filings, most recently posting 40878000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 40878000.0, down 85.64% year-over-year; the trailing twelve-month figure through Mar 2026 was 111948000.0 (down 34.15% YoY), and the FY2025 annual result was 93090000.0, down 14.61% from the prior year.
• Cash from Operations came in at 40878000.0 for Q1 2026 at Taysha Gene Therapies, down from 26722000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 14712000.0 in Q4 2022 to a low of 40939000.0 in Q1 2022.
• The 5-year median for Cash from Operations is 21504000.0 (2024), against an average of 22153000.0.
• Across the five-year window, Cash from Operations soared 136.54% in 2022 and plunged 209.55% in 2023, its largest moves.
• Taysha Gene Therapies' Cash from Operations stood at 14712000.0 in 2022, then slumped by 209.55% to 16117000.0 in 2023, then dropped by 13.59% to 18308000.0 in 2024, then slumped by 45.96% to 26722000.0 in 2025, then plunged by 52.98% to 40878000.0 in 2026.
• The last three Cash from Operations figures came in at 40878000.0 (Q1 2026), 26722000.0 (Q4 2025), and 24166000.0 (Q3 2025), per Business Quant data.